Floatz logo

Auto-Cd34+ Cells

Myocardial Ischemia

Lisata Therapeutics, Inc.Cell therapyPhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Myocardial Ischemia cohort.

Asset / SponsorPhaseRating
Ranolazine
East Carolina University
Phase 4A
Atenolol
Xintong Pharmacy Company
Phase 4BBB
Aspirin
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
Nebido
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 4BB
3-(2,2,2-TRIMETHYLDIAZANIUMYL)PROPANOATE
Burnasyan Federal Medical Biophysical Center
Phase 4BB

View all 27 →

Same molecule, other indications

Auto-Cd34+ Cells is also rated in:

coronary artery disorderDormant
BB
Indicative · Phase 3
66 / 100
View asset →
ischemic diseaseDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →
ulcer diseaseDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →